Recommendations for the standardization and interpretation of the electrocardiogram

Part II: Electrocardiography diagnostic statement list

A Scientific Statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society

Endorsed by the International Society for Computerized Electrocardiology

Jay W. Mason, MD, FAHA, FACC, FHRS; E. William Hancock, MD, FACC; Leonard S. Gettes, MD, FAHA, FACC

Abstract— This statement provides a concise list of diagnostic terms for ECG interpretation that can be shared by students, teachers, and readers of electrocardiography. This effort was motivated by the existence of multiple automated diagnostic code sets containing imprecise and overlapping terms. An intended outcome of this statement list is greater uniformity of ECG diagnosis and a resultant improvement in patient care. The lexicon includes primary diagnostic statements, secondary diagnostic statements, modifiers, and state-

This is the second of 6 articles designed to upgrade the guidelines for the standardization and interpretation of the ECG. The project was initiated by the American Heart Association and has been endorsed by the American College of Cardiology, the Heart Rhythm Society, and the International Society for Computerized Electrocardiography. The rationale for this upgrade and a description of the process are contained in Part I by Kligfield et al.¹

The listing contained in the present statement seeks to

Other members of the Standardization and Interpretation of the Electrocardiogram Writing Group include James J. Bailey, MD; Rory Childers, MD; Barbara J. Deal, MD, FACC; Mark Josephson, MD, FACC, FHRS; Paul Kligfield, MD, FAHA, FACC; Jan A. Kors, PhD; Peter Macfarlane, DSc; Olle Pahlm, MD, PhD; David M. Mirvis, MD, FAHA; Peter Okin, MD, FACC; Pentti Rautaharju, MD, PhD; Borys Surawicz, MD, FAHA, FACC; Gerard van Herpen, MD, PhD; Galen S. Wagner, MD; and Hein Wellens, MD, FAHA, FACC.

The American Heart Association, the American College of Cardiology, and the Heart Rhythm Society make every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.

This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on October 26, 2006, by the American College of Cardiology Board of Trustees on October 12, 2006, and by the Heart Rhythm Society on September 6, 2006.

When citing this document, the American Heart Association, the

ments for the comparison of ECGs. This diagnostic lexicon should be reviewed and updated periodically.

KEYWORDS AHA Scientific Statements; electrocardiography; computers; diagnosis

(Heart Rhythm 2007;4:413-419) © 2007 Heart Rhythm Society, American Heart Association, and the American College of Cardiology Foundation. All rights reserved.

present a limited set of ECG diagnostic statements that are clinically useful and that do not create unnecessary overlap or contain vague terminology. Some statements that are commonly used by electrocardiographers but that do not provide diagnostically or clinically useful information are not included. Some statements have been excluded to reduce the size of the statement set, so long as their meaning is well represented by included terms.

The Writing Group believes that the listing should be im-

American College of Cardiology Foundation, and the Heart Rhythm Society request that the following citation format be used: Mason JW, Hancock EW, Gettes LS. Recommendations for the standardization and interpretation of the electrocardiogram: part II: electrocardiography diagnostic statement list: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Heart Rhythm 2007;4:413–419.

This article has been copublished in the March 13, 2007, issue of *Circulation* and in the March 13, 2007 issue of the *Journal of the American College of Cardiology*.

Copies: For copies of this document, please contact Elsevier Inc. Reprint Department, fax (212) 633-3820, e-mail reprints@elsevier. com.

Permissions: Modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at http://www.americanheart.org/presenter.jhtml?Identifier=4431. A link to the "Permission Request Form" appears on the right side of the page.

plemented as an available lexicon in report algorithms of the existing commercial electrocardiographs and that it should be used widely by ECG readers. The principal advantage of such use would be a worldwide improvement in uniformity of ECG interpretation. Such uniformity would promote better patient care. Additional advantages would be facilitation of the establishment of a uniform teaching curriculum in electrocardiography, availability of a uniform glossary of terms for research application, and promotion of research to better validate diagnostic criteria for the specific terms in the limited lexicon.

Although we recognize that each vendor of ECGs possesses a proprietary set of diagnostic statements and underlying criteria, we hope that this list of statements will be made available by each of them so that the reader can select it as the primary dictionary for use in interpreting all or some ECGs. We are also hopeful that the vendors will collaborate among themselves to align diagnostic criteria for this specific lexicon. This would not interfere with continued development of entirely independent, proprietary diagnostic software by each manufacturer.

Organization and use

Four lists are included within this document. The main listing (Table 1), "Primary Statements," displays 117 primary diagnostic statements under 14 categories. The majority of the primary statements are nondescriptive and convey clinical meaning without additional statements. The second listing (Table 2), "Secondary Statements," provides additional statements that can be used to expand the specificity and clinical relevance of both descriptive and other primary diagnostic statements. These secondary statements are divided into 2 groups. Those that are preceded by "suggests" invoke clinical diagnoses likely responsible for the ECG observation(s). Those that are preceded by "consider" are intended to propose at least 1, but sometimes >1, potentially associated clinical disorder. This set of primary and secondary diagnostic statements constitutes what we might call the "core statement lexicon."

The third list (Table 3) contains adjectives that can be used to modify the diagnostic statements. None of the modifiers change the meaning of the core statement but rather serve to refine the meaning. The list contains general modifiers, which can be used with many of the core statements, and specific modifiers assigned to a specific category of statements.

The fourth list (Table 4) is a short directory of comparison statements. It specifies 6 types of ECG changes that merit mention in the ECG interpretation and defines criteria to identify change within the 6 categories. Because so many statements could be made in comparing individual ECGs to ≥ 1 previous ECGs, the Writing Group recommends use of these 6 statements to convey clinically important information that could influence patient care by the attending physician while preserving brevity and uniformity. On the other hand, the Writing Group encourages readers to add uncoded text as needed to the report to more fully compare tracings. Tables 5, 6, and 7 establish rules for use of the primary, secondary, and modifier statements, alone or in combination. Table 8 is a set of commonly used statements that can, for the most part, be precisely reproduced by use of the primary and secondary statements and their modifiers. These statements are commonly used concatenations provided for the convenience of the reader.

Criteria for diagnoses

This listing does not specify diagnostic criteria for any of the statements. A single set of diagnostic criteria underlying the core statements would have great benefits for patient care and research. Although the Writing Group does not believe that a uniform criterion set can be achieved at this time, we encourage ECG vendors and electrocardiography researchers and experts to collaborate on the development of a universally acceptable criteria set and a means for perpetually refining it. Several of the chapters in this statement support specific criteria for some of the core statements.

Myocardial infarction terminology

Advanced imaging techniques, including echocardiography² and magnetic resonance,^{3,4} have demonstrated a need for change in existing terminology describing the cardiac location of myocardial infarction. New diagnostic statements for 6 common, distinct cardiac locations of myocardial infarction, documented by contrast-enhanced magnetic resonance, were recently recommended by a committee of the International Society for Holter and Noninvasive Electrocardiography.⁵ At the present time, the Writing Group considers the quantity of new data insufficient to recommend abandonment of existing terminology. Thus, traditional terms are listed in "Section M: Myocardial infarction" of the primary statement table (Table 1); however, we intend to revisit this issue when sufficient data have been developed.

References

- Kligfield P, Gettes L, Bailey JJ, et al. Recommendations for the standardization and interpretation of the electrocardiogram: part I: the electrocardiogram and its technology: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Heart Rhythm 2007;4:394–412.
- Bogaty P, Boyer L, Rousseau L, Arsenault M. Is anteroseptal myocardial infarction an appropriate term? Am J Med 2002;113:37–41.
- Selvanayagam JB, Kardos A, Nicolson D, et al. Anteroseptal or apical myocardial infarction: a controversy addressed using delayed enhancement cardiovascular magnetic resonance imaging. J Cardiovasc Magn Reson 2004; 6:653–61.
- Bayes de Luna A, Cino JM, Pujadas S, et al. Concordance of electrocardiographic patterns and healed myocardial infarction location detected by cardiovascular magnetic resonance. Am J Cardiol 2006;97:443–51.
- 5. Bayes de Luna A, Wagner G, Birnbaum Y, et al; International Society for Holter and Noninvasive Electrocardiography. A new terminology for left ventricular walls and location of myocardial infarcts that present Q wave based on the standard of cardiac magnetic resonance imaging: a statement for healthcare professionals from a committee appointed by the International Society for Holter and Noninvasive Electrocardiography. Circulation 2006;114:1755–60.

Disclosures

Writing group disclosures

| Writing group member | Employment | Research grant | Other research support | Speakers' bureau/ honoraria | Ownership Interest | Consultant/ Advisory Board | Other |
|-------------------------|------------------------------------|-------------------|------------------------------|-----------------------------------|-----------------------|---|-------|
| Jay W. Mason | Covance Cardiac Safety Services | None | None | None | None | None | None |
| Leonard S. Gettes | University of North Carolina | None | None | None | None | None | None |
| E. William Hancock | Stanford University Medical Center | None | None | None | None | Philips Medical Systems,* Covance Diagnostics* | None |

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be "significant" if (1) the person receives \$10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (2) the person owns 5% or more of the voting stock or share of the entity, or owns \$10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition. *Significant.

Reviewer disclosures

| Reviewer | Employment | Research grant | Other research support | Speakers' bureau/ honoraria | Ownership interest | Consultant/ Advisory Board | Other |
|--------------------|---|---|------------------------------|-----------------------------------|-----------------------|-------------------------------|-----------------------------|
| Jonathan Abrams | University of New Mexico | None | None | None | None | None | None |
| Leonard S. Dreifus | Hahnemann University, School of Medicine | None | None | None | None | None | Merck Endpoint Committee |
| Mark Eisenberg | McGill University | None | None | None | None | None | None |
| Nora Goldschlager | University of California, San Francisco | None | None | St. Jude; Medtronic | None | None | None |
| Peter Kowey | Lankenau Hospital and Main Line Health | None | None | Medifacts | Cardionet | Medifacts | None |
| Frank Marcus | University of Arizona | None | None | None | None | None | None |
| Thomas M. Munger | Mayo Clinic | St. Jude Medical, Bard Electrophysiology | None | None | None | None | None |
| Robert J. Myerburg | University of Miami | None | None | None | None | None | None |
| David Rosenbaum | Case Western Reserve University | None | None | None | None | None | None |
| Richard Schofield | University of Florida | None | None | None | None | None | None |
| Samuel Shubrooks | Beth Israel Deaconess Medical Center | None | None | None | None | None | None |
| Cynthia Tracy | George Washington University | None | None | None | None | None | None |

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit.

Table 1 Primary Statements

| A. Overa | all interpretation | H. Atriov | ventricular conduction |
|---------------|--|-----------|--|
| 1 | Normal ECG | 80 | Short PR interval |
| 2 | Otherwise normal ECG | 81 | AV conduction ratio N:D |
| 3 | Abnormal ECG | 82 | Prolonged PR interval |
| 4 | Uninterpretable ECG | 83 | Second-degree AV block, Mobitz type I (Wenckebach) |
| B. Tech | nical conditions | 84 | Second-degree AV block, Mobitz type II |
| 10 | Extremity electrode reversal | 85 | 2:1 AV block |
| 11 | Misplaced precordial electrode(s) | 86 | AV block, varying conduction |
| 12 | Missing lead(s) | 87 | AV block, advanced (high-grade) |
| 13 | Right-sided precordial electrode(s) | 88 | AV block, complete (third-degree) |
| 14 | Artifact | 89 | AV dissociation |
| 15 | Poor-quality data | I. Intrav | entricular and intra-atrial conduction |
| 16 | Posterior electrode(s) | 100 | Aberrant conduction of supraventricular beat(s) |
| C. Sinus | node rhythms and arrhythmias | 101 | Left anterior fascicular block |
| 20 | Sinus rhythm | 102 | Left posterior fascicular block |
| 21 | Sinus tachycardia | 104 | Left bundle-branch block |
| 22 | Sinus bradycardia | 105 | Incomplete right bundle-branch block |
| 23 | Sinus arrhythmia | 106 | Right bundle-branch block |
| 24 | Sinoatrial block, type I | 107 | Intraventricular conduction delay |
| 25 | Sinoatrial block, type II | 108 | Ventricular preexcitation |
| 26 | Sinus pause or arrest | 109 | Right atrial conduction abnormality |
| 27 | Uncertain supraventricular rhythm | 110 | Left atrial conduction abnormality |
| D. Supra | aventricular arrhythmias | 111 | Epsilon wave |
| 30 | Atrial premature complex(es) | J. Axis a | and voltage |
| 31 | Atrial premature complexes, nonconducted | 120 | Right-axis deviation |
| 32 | Retrograde atrial activation | 121 | Left-axis deviation |
| 33 | Wandering atrial pacemaker | 122 | Right superior axis |
| 34 | Ectonic atrial rhythm | 123 | Indeterminate axis |
| 35 | Ectopic atrial rhythm multifocal | 124 | Flectrical alternans |
| 36 | Junctional premature complex(es) | 125 | Low voltage |
| 37 | Junctional escape complex(es) | 128 | Abnormal precordial R-wave progression |
| 38 | Junctional rhythm | 131 | Abnormal P-wave axis |
| 30 | Accelerated junctional rhythm | K Cham | her hypertronhy or enlargement |
| 40 | Supraventricular rhythm | 140 | Left atrial enlargement |
| 40 | Supraventricular complex(es) | 140 | Right atrial enlargement |
| /2 | Bradycardia nonsinus | 1/2 | left ventricular hypertronhy |
| F Supra | aventricular tachyarrhythmias | 1/3 | Right ventricular hypertrophy |
| 50 E. Supre | Atrial fibrillation | 145 | Biventricular hypertrophy |
| 50 | Atrial fluttor | | amont T wave and II wave |
| 52 | Ectopic atrial tachycardia, unifocal | 1/5 | ST deviation |
| 52 | Ectopic atrial tachycardia, multifocal | 145 | ST deviation with T ways change |
| 55 | Junctional tachycardia | 140 | T wave abnormality |
| 54 | Supraventricular tachycardia | 147 | Prolonged OT interval |
| 55 | Narrow OPS tachycardia | 140 | Short OT interval |
| 50 E Vonte | Nallow-UKS Lacifycalula | 149 | Brominent II waves |
| r. venu | icular armythinias | 150 | Prominent U waves |
| 0U | ventricular premature complex(es) | 151 | There of waves |
| 01 | rusion complex(es) | 152 | |
| 62 | Ventricular escape complex(es) | 153 | SI-I change due to ventricular hypertrophy |
| 63 | Idioventricular rhythm | 154 | Usborn wave |
| 64 | Accelerated idioventricular rhythm | 155 | Early repolarization |
| 65 | Fascicular rhythm | M. Myoc | ardial infarction |
| 66 | Parasystole | 160 | Anterior MI |
| G. Vent | ncular tachyarrhythmias | 161 | Interior MI |
| 70 | Ventricular tachycardia | 162 | Posterior MI |
| 71 | Ventricular tachycardia, unsustained | 163 | Lateral MI |
| 72 | Ventricular tachycardia, polymorphous | 165 | Anteroseptal MI |
| 73 | Ventricular tachycardia, torsades de pointes | 166 | Extensive anterior MI |
| 74 | Ventricular fibrillation | 173 | MI in presence of left bundle-branch block |
| | Fascicular tachycardia | 174 | Right ventricular MI |
| 75 | · | | |

Table 1 Primary Statements, Cont'd

| N. Pacema | ker |
|-----------|---|
| 180 | Atrial-paced complex(es) or rhythm |
| 181 | Ventricular-paced complex(es) or rhythm |
| 182 | Ventricular pacing of non-right ventricular apical origin |
| 183 | Atrial-sensed ventricular-paced complex(es) or rhythm |
| 184 | AV dual-paced complex(es) or rhythm |
| 185 | Failure to capture, atrial |
| 186 | Failure to capture, ventricular |
| 187 | Failure to inhibit, atrial |
| 188 | Failure to inhibit, ventricular |
| 189 | Failure to pace, atrial |
| 190 | Failure to pace, ventricular |

AV indicates atrioventricular; MI, myocardial infarction.

Table 2 Secondary Statements

| Suggests | |
|----------|------------------------------------|
| 200 | Acute pericarditis |
| 201 | Acute pulmonary embolism |
| 202 | Brugada abnormality |
| 203 | Chronic pulmonary disease |
| 204 | CNS disease |
| 205 | Digitalis effect |
| 206 | Digitalis toxicity |
| 207 | Hypercalcemia |
| 208 | Hyperkalemia |
| 209 | Hypertrophic cardiomyopathy |
| 210 | Hypocalcemia |
| 211 | Hypokalemia or drug effect |
| 212 | Hypothermia |
| 213 | Ostium primum ASD |
| 214 | Pericardial effusion |
| 215 | Sinoatrial disorder |
| Consider | |
| 220 | Acute ischemia |
| 221 | AV nodal reentry |
| 222 | AV reentry |
| 223 | Genetic repolarization abnormality |
| 224 | High precordial lead placement |
| 225 | Hypothyroidism |
| 226 | Ischemia |
| 227 | Left ventricular aneurysm |
| 228 | Normal variant |
| 229 | Pulmonary disease |
| 230 | Dextrocardia |
| 231 | Dextroposition |

CNS indicates central nervous system; ASD, atrial septal defect; and AV, atrioventricular.

| Table 3 Modifiers | |
|--|-----------------------------------|
| General | |
| 301 | Borderline |
| 303 | Increased |
| 304 | Intermittent |
| 305 | Marked |
| 306 | Moderate |
| 307 | Multiple |
| 308 | Uccasional |
| 309 | Une |
| 310 | Frequent |
| 312 | Possible |
| 313 | Postoperative |
| 314 215 | Preuominant |
| 216 | Prominant |
| 217 | (Specified) Load(s) |
| 210 | (Specified) Electroda(s) |
| 221 | Nonspecific |
| General: conjunctions | Nonspecific |
| 302 | Consider |
| 310 | Or |
| 320 | And |
| 319 | With |
| 322 | Versus |
| Mvocardial infarction | |
| 330 | Acute |
| 331 | Recent |
| 332 | Old |
| 333 | Of indeterminate age |
| 334 | Evolving |
| Arrhythmias and tachyarrhyth | nias |
| 340 | Couplets |
| 341 | In a bigeminal pattern |
| 342 | In a trigeminal pattern |
| 343 | Monomorphic |
| 344 | Multifocal |
| 345 | Unifocal |
| 346 | With a rapid ventricular response |
| 347 | With a slow ventricular response |
| 348 | With capture beat(s) |
| 349 | With aderrancy |
| 350 Developing tion observabilities | Polymorphic |
| | >0.1 mV |
| 261 | $\geq 0.1 \text{ mV}$ |
| 362 | ≥0.2 IIIV |
| 363 | Flevation |
| 364 | Maximally toward lead |
| 365 | Maximally away from lead |
| 366 | low amplitude |
| 367 | Inversion |
| 369 | Postpacing (anamnestic) |

Code Statement Criteria 400 No significant change Intervals (PR, QRS, QTc) remain normal or within 10% of a previously abnormal value No new or deleted diagnoses with the exception of normal variant diagnoses 401 Significant change in rhythm New or deleted rhythm diagnosis HR change >20 bpm and <50 or >100 bpm New or deleted pacemaker diagnosis 402 New or worsened ischemia or Added infarction, ST-ischemia, or T-wave-ischemia diagnosis, or worsened infarction ST deviation or T-wave abnormality 403 New conduction abnormality Added AV or IV conduction diagnosis 404 Significant repolarization change New or deleted QT diagnosis New or deleted U-wave diagnosis New or deleted nonischemic ST or T-wave diagnosis Change in QTc >60 ms New or deleted diagnosis from Axis and Voltage, Chamber Hypertrophy, or 405 Change in clinical status Enlargement primary statement categories or "Suggests. . ." secondary statement category 406 Change in interpretation without Used when a primary or secondary statement is added or removed despite significant change in waveform no real change in the tracing; ie, an interpretive disagreement exists between the readers of the first and second ECGs

 Table 4
 Comparison Statements

QTc indicates corrected QT interval; HR, heart rate; bpm, beats per minute; AV, atrioventricular; and IV, intraventricular.

Table 5 General Use Rules

| 1 | Secondary statements must be accompanied by a primary |
|---|---|
| | statement |
| 2 | Modifiers must be accompanied by a primary statement |
| 3 | A primary statement may be accompanied by nothing, by ≥ 1 modifiers, by ≥ 1 secondary statements, or by both. |
| 4 | Each secondary statement can accompany only certain |
| _ | primary statements (see Table 0) |
| 5 | Each general modifier can accompany only certain primary statements (see Table 7) |
| 6 | Each specific modifier can accompany only primary statements within its category |
| | |

Table 6 Secondary–Primary Statement Pairing Rules

| Secondary Code | May Accompany These Primary Codes |
|----------------|--|
| 200 | 145–147 |
| 201 | 21, 105, 109, 120, 131, 141, 145–147 |
| 202 | 105, 106, 145–146 |
| 203 | 109, 120, 125, 128, 131, 141, 143 |
| 204 | 147 |
| 205 | 145–147 |
| 206 | 145–147 |
| 207 | 149 |
| 208 | 147 |
| 209 | 142 |
| 210 | 148 |
| 211 | 147–148, 150 |
| 212 | 14, 154 |
| 213 | 82, 105–106, 121 |
| 214 | 124 |
| 215 | 42, 131, 145–147 |
| 220 | 145–147, 151 |
| 221 | 55, 56 |
| 222 | 55, 56 |
| 223 | 148, 149 |
| 224 | 128 |
| 225 | 22, 24–26, 37, 38 |
| 226 | 145–147 |
| 227 | 145–147 |
| 228 | 80, 105, 128, 155 |
| 229 | 109, 120, 122–123, 125, 128, 131, 141, 143 |
| 230 | 128, 131 |
| 231 | 128 |

| General Modifier Code | May (May Not) Accompany These Primary Codes or May Be Between Codes in These Categories or Groups of Categories | May/ May Not | Location |
|--------------------------|--|-----------------|----------|
| 301 | 1-20, 24-76, 81, 83-106, 108, 122-124 | May not | b |
| 302 | 1–3, 12–16, 80–82, 111–130, 145–152 | May not | b, i |
| 303 | 30, 31, 36, 37, 41, 60, 62, 63, 82, 107, 109, 110 | May | a, b |
| 304 | 21-26, 30-76, 80, 82-108, 124, 180-190 | May | b |
| 305 | 1–20, 27–76, 81, 85–106, 111, 122, 123, 148–150, 160–190 | May not | b |
| 306 | 1–20, 27–76, 81, 85–106, 111, 122, 123, 148–150, 160–190 | May not | b |
| 307 | 26, 30, 31, 36, 37, 41, 60-62, 185-190 | May | b |
| 308 | 26, 30, 31, 36, 37, 41, 60-62, 185-190 | May | b |
| 309 | 26, 30, 31, 36, 37, 41, 60-62, 185-190 | May | b |
| 310 | C, D, E, F, G, N, H, I, J, K, L, M | May | i |
| 312 | 1-3, 15, 80-82, 120-122, 128 | May not | b |
| 313 | 145–147 | May | b |
| 314 | 20-23, 33-35, 38-56, 63-76, 83-89, 180-184 | May | b |
| 315 | 1-3, 15, 80-82, 120-122, 128 | May not | b |
| 316 | 1-20, 27-76, 81, 85-106, 111, 122, 123, 148-150, 160-190 | May not | b |
| 317 | C, D, E, F, G, N, H, I, J, K, L, M | May | i |
| 318 | C, D, E, F, G, N, H, I, J, K, L, M | May | i |
| 319 | C, D, E, F, G, N, 100, J, K, L, M | May | i |
| 321 | 40, 55, 56, 145–147 | May | b |

Table 7 General Modifier-Primary Statement Pairing Rules*

b indicates before; a, after; and i, between.

*Not inclusive.

Table 8 Convenience Statements*

| Code | Statement |
|------|------------------------------|
| 500 | Nonspecific ST-T abnormality |
| 501 | ST elevation |
| 502 | ST depression |
| 503 | LVH with ST-T changes |
| | Others to be added |

LVH indicates left ventricular hypertrophy.

*This table will be developed independently by each ECG laboratory.